Editas Medicine to present at investor conferences in September.
PorAinvest
miércoles, 27 de agosto de 2025, 9:03 am ET1 min de lectura
EDIT--
The conferences include the Wells Fargo Healthcare Conference on September 3 in Boston, the Cantor Global Healthcare Conference on September 4 in New York, and the Baird Global Healthcare Conference on September 9 in New York. These events provide investors with an opportunity to engage with Editas Medicine's management team and gain insights into the company's pipeline and future plans.
Editas Medicine's participation in these conferences follows its recent strong performance, as highlighted by a robust 34% week-to-date increase in its share price. The company's second-quarter earnings report, released on Tuesday, showed revenue of slightly under $3.6 million, up from $513,000 in the same quarter last year. Although the company missed earnings expectations, its operational update and future outlook drove investor enthusiasm [1].
The company's CEO, Gilmore O'Neill, stated that Editas is "driving toward our goal of nominating our first in vivo development candidate, which we plan to select in September." This announcement was a significant driver of the stock's performance and generated excitement among investors [1].
Investors interested in Editas Medicine's presentations and one-on-one meetings can access the live webcasts (where available) by visiting the "Investors" section of the company's website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.
References:
[1] https://www.aol.com/why-editas-medicine-stock-skyrocketing-115043661.html
[2] https://www.marketscreener.com/news/editas-medicine-to-participate-in-upcoming-investor-conferences-ce7c50dedc81ff23
Editas Medicine, a gene editing company, announced management participation in three upcoming investor conferences in September. The conferences include the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, and Baird Global Healthcare Conference. Editas Medicine's presentations and one-on-one meetings will be available via webcast on the company's website.
Editas Medicine, Inc. (NASDAQ: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, has announced its management team's participation in three upcoming investor conferences in September. The company's presentations and one-on-one meetings will be available via webcast on the company's website.The conferences include the Wells Fargo Healthcare Conference on September 3 in Boston, the Cantor Global Healthcare Conference on September 4 in New York, and the Baird Global Healthcare Conference on September 9 in New York. These events provide investors with an opportunity to engage with Editas Medicine's management team and gain insights into the company's pipeline and future plans.
Editas Medicine's participation in these conferences follows its recent strong performance, as highlighted by a robust 34% week-to-date increase in its share price. The company's second-quarter earnings report, released on Tuesday, showed revenue of slightly under $3.6 million, up from $513,000 in the same quarter last year. Although the company missed earnings expectations, its operational update and future outlook drove investor enthusiasm [1].
The company's CEO, Gilmore O'Neill, stated that Editas is "driving toward our goal of nominating our first in vivo development candidate, which we plan to select in September." This announcement was a significant driver of the stock's performance and generated excitement among investors [1].
Investors interested in Editas Medicine's presentations and one-on-one meetings can access the live webcasts (where available) by visiting the "Investors" section of the company's website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.
References:
[1] https://www.aol.com/why-editas-medicine-stock-skyrocketing-115043661.html
[2] https://www.marketscreener.com/news/editas-medicine-to-participate-in-upcoming-investor-conferences-ce7c50dedc81ff23
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios